BioNTech (NASDAQ:BNTX) Rating Reiterated by HC Wainwright
BioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $113.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 40.58% from the stock’s previous close. A number of […]
More Stories
The Goldman Sachs Group (NYSE:GS) PT Raised to $577.00 at Oppenheimer
The Goldman Sachs Group (NYSE:GS – Get Free Report) had its price target increased by equities research analysts at Oppenheimer...
Piper Sandler Increases Horace Mann Educators (NYSE:HMN) Price Target to $36.00
Horace Mann Educators (NYSE:HMN – Get Free Report) had its price objective hoisted by research analysts at Piper Sandler from...
Voya Financial (NYSE:VOYA) PT Raised to $88.00 at Piper Sandler
Voya Financial (NYSE:VOYA – Get Free Report) had its price objective upped by analysts at Piper Sandler from $84.00 to...
Comerica (NYSE:CMA) Price Target Increased to $64.00 by Analysts at Evercore ISI
Comerica (NYSE:CMA – Get Free Report) had its price target lifted by research analysts at Evercore ISI from $58.00 to...
Marinus Pharmaceuticals (NASDAQ:MRNS) Raised to Strong-Buy at EF Hutton Acquisition Co. I
EF Hutton Acquisition Co. I upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) to a strong-buy rating in a...
Jefferies Financial Group Downgrades ZIM Integrated Shipping Services (NYSE:ZIM) to Hold
ZIM Integrated Shipping Services (NYSE:ZIM – Get Free Report) was downgraded by research analysts at Jefferies Financial Group from a...